The Interaction of Lipophilic Drugs with Intestinal Fatty Acid-binding Protein
Open accessThe DOI matches its Crossref record.
Abstract
Intestinal fatty acid-binding protein (I-FABP) is a small protein that binds long-chain dietary fatty acids in the cytosol of the columnar absorptive epithelial cells (enterocytes) of the intestine. The binding cavity of I-FABP is much larger than is necessary to bind a fatty acid molecule, which suggests that the protein may be able to bind other hydrophobic and amphipathic ligands such as lipophilic drugs. Herein we describe the binding of three structurally diverse lipophilic drugs, bezafibrate, ibuprofen (both R- and S-isomers) and nitrazepam to I-FABP. The rank order of affinity for I-FABP determined for these compounds was found to be R-ibuprofen approximately bezafibrate > S-ibuprofen >> nitrazepam. The binding affinities were not directly related to aqueous solubility or partition coefficient of the compounds; however, the freely water-soluble drug diltiazem showed no affinity for I-FABP. Drug-I-FABP interaction interfaces were defined by analysis of chemical shift perturbations in NMR spectra, which revealed that the drugs bound within the central fatty acid binding cavity. Each drug participated in a different set of interactions within the cavity; however, a number of common contacts were observed with residues also involved in fatty acid binding. These data suggest that the binding of non-fatty acid lipophilic drugs to I-FABP may increase the cytosolic solubility of these compounds and thereby facilitate drug transport from the intestinal lumen across the enterocyte to sites of distribution and metabolism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Lipids and Lipid-Based Formulations: Optimizing the Oral Delivery of Lipophilic Drugs
Porter, C. J. H., Trevaskis, N. L., & Charman, W. N. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2197 · Cited by 1,824
“Lipids and changes to enterocyte biology The potential for lipids and lipidic excipients to interact with lipid and drug transport pathways into and across the enterocyte has emerged as a growing area of interes”
BackgroundSelf-citationWhen poor solubility becomes an issue: From early stage to proof of concept
Stegemann, S., Leveiller, F., Franchi, D., de Jong, H., & Lindén, H. (2007) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2007.05.110 · Cited by 567
The human fatty acid-binding protein family: Evolutionary divergences and functions
Smathers, R. L., & Petersen, D. R. (2011) · Human Genomics · doi:10.1186/1479-7364-5-3-170 · Cited by 492
Lipid-Based Delivery Systems and Intestinal Lymphatic Drug Transport: A Mechanistic Update
Trevaskis, N. L., Charman, W. N., & Porter, C. J. H. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.09.007 · Cited by 442
“For example, structural studies have demonstrated that I-FABP and L-FABP bind with relatively high affinity to certain drugs, and in particular those with structural similarities to the endogenous ligand FA [114,115].”
BackgroundSelf-citationSheng, N., Cui, R., Wang, J., Guo, Y., Wang, J., & Dai, J. (2018) · Archives of Toxicology · doi:10.1007/s00204-017-2055-1 · Cited by 295
Metadata
- Authors
- Velkov, T., Chuang, S., Wielens, J., Sakellaris, H., Charman, W. N., Porter, C. J. H., & Scanlon, M. J.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2005-05
- Volume
- 280
- Issue
- 18
- Pages
- 17769-17776
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W1966887582
- Cited by
- 61
- References
- 0
- FWCI
- 1.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Interaction of Lipophilic Drugs with Intestinal Fatty Acid-binding Protein. https://app.cochat.ai/papers/10.1074/jbc.m410193200
- The paper
- Velkov, T., Chuang, S., Wielens, J., Sakellaris, H., Charman, W. N., Porter, C. J. H., & Scanlon, M. J. (2005). The Interaction of Lipophilic Drugs with Intestinal Fatty Acid-binding Protein. Journal of Biological Chemistry. https://doi.org/10.1074/jbc.m410193200
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.